A Phase 2, Randomized, Double-blinded, Placebo-controlled Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)

The purpose of this study is to evaluate the safety, tolerability, preliminary efficacy, and pharmacokinetics (PK) of efimosfermin in participants with metabolic dysfunction associated steatohepatitis (MASH) and compensated cirrhosis consistent with stage F4 fibrosis.

开始日期2025-04-09

申办/合作机构

Boston Pharmaceuticals, Inc.

NCT04880031

/ Active, not recruiting临床2期

A Phase 2a, Randomized, Blinded, Placebo-controlled Study of BOS-580 in Obese Subjects at Risk for, or With Biopsy-confirmed, Nonalcoholic Steatohepatitis (NASH) With a Single Arm Open-label Extension

This is a randomized, blinded, placebo-controlled study of Efimosfermin in obese participants at risk for, or with biopsy-confirmed, nonalcoholic steatohepatitis (NASH), with a single arm open-label extension. It includes Parts A, B, C and D.

开始日期2021-09-30

申办/合作机构

Boston Pharmaceuticals, Inc.

NCT03466203

/ Completed临床1期

A 12 Week Phase Ib Randomized Investigator and Subject Blinded Placebo Controlled Repeat-dose Study of LLF580

The purpose of the study is to evaluate the safety and tolerability of multiple doses of LLF580 administered subcutaneously over 3 months in obese subjects. In addition, the study will also determine early efficacy signals in various metabolic diseases associated with elevated triglycerides and/or obesity.

开始日期2018-02-26

申办/合作机构

Novartis Pharmaceuticals Corp.

100 项与 Efimosfermin alfa 相关的临床结果

登录后查看更多信息

100 项与 Efimosfermin alfa 相关的转化医学

登录后查看更多信息

100 项与 Efimosfermin alfa 相关的专利（医药）

登录后查看更多信息

项与 Efimosfermin alfa 相关的文献（医药）

2022-01-01·The Journal of clinical endocrinology and metabolism2区 · 医学

LLF580, an FGF21 Analog, Reduces Triglycerides and Hepatic Fat in Obese Adults With Modest Hypertriglyceridemia

2区 · 医学

Article

作者: Nguyen, Amanda ; Hinder, Markus ; Kompa, Jill ; Basson, Craig T ; Hunt, Allen ; Escalon, Maricer ; Fein, Melanie ; Bajaj, Archna ; Li, Yifang ; Hom, Doug ; Ferriere, Michael ; Rader, Daniel J ; Goldfine, Allison B ; Maratos-Flier, Eleftheria ; Kankam, Martin K ; Koren, Michael ; Martic, Miljen ; Diener, John ; Wilson, Jessica ; Yowe, David

Abstract:

Purpose:

To evaluate the safety and potential efficacy of LLF580, a genetically engineered variant of human fibroblast growth factor-21, for triglyceride lowering, weight loss, and hepatic fat reduction.

Methods:

A multicenter, double-blind, parallel design trial in obese, mildly hypertriglyceridemic adults randomized (1:1) to LLF580 300 mg or placebo subcutaneously every 4 weeks for 3 doses.

Results:

Of 64 randomized study participants, 61 (mean ± SD: age 45 ± 11 years, 49% male, 80/15/5% Caucasian/African American/other, body mass index 36.1 ± 3.8 kg/m2) received LLF580 (n = 30) or placebo (n = 31) at 7 research sites in the United States. LLF580 lowered serum triglycerides by 54% (least square mean placebo adjusted change from baseline), total cholesterol 7%, low-density lipoprotein cholesterol 12%, and increased high-density lipoprotein cholesterol 36% compared with placebo (all P < 0.001) over 12 weeks. Substantial reduction of liver fat of 52% over placebo (P < 0.001) was also demonstrated in the setting of improved liver function tests including alanine aminotransferase, aspartate aminotransferase, and alkaline phosphatase, the composite enhanced liver fibrosis score, and N-terminal type III collagen propeptide (all P < 0.05). Insulin and C-peptide levels and insulin resistance by homeostatic model assessment for insulin resistance were all lower, and adiponectin higher with LLF580 treatment compared with placebo, whereas fasting glucose and glycated hemoglobin were unchanged. Reductions in biomarkers of bone formation without differences in markers of bone resorption were observed. LLF580 was generally safe and well tolerated, except for higher incidence of generally mild to moderate gastrointestinal adverse effects.

Conclusions:

In obese, mildly hypertriglyceridemic adults, LLF580 was generally safe and demonstrated beneficial effects on serum lipids, liver fat, and biomarkers of liver injury, suggesting it may be effective for treatment of select metabolic disorders including hypertriglyceridemia and nonalcoholic fatty liver disease. Assessments of longer term safety and efficacy are warranted.

ClinicalTrials.gov Identifier:

NCT03466203

Therapeutics and clinical risk management

Fibroblast Growth Factor-21 as a Potential Therapeutic Target of Nonalcoholic Fatty Liver Disease

Review

作者: Mantzoros, Christos S ; Raptis, Dimitrios D ; Polyzos, Stergios A

Nonalcoholic fatty liver disease (NAFLD) is a highly prevalent disease without any approved treatment to-date despite intensive research efforts by researchers and pharmaceutical industry. Fibroblast growth factor (FGF)-21 has been gaining increasing attention as a possible contributing factor and thus therapeutic target for obesity-related metabolic disorders, including NAFLD, mainly due to its effects on lipid and carbohydrate metabolism. Most animal and human observational studies have shown higher FGF-21 concentrations in NAFLD than non-NAFLD, implying that FGF-21 may be increased to counteract hepatic steatosis and inflammation. However, although Mendelian Randomization studies have revealed that variations of FGF-21 levels within the physiological range may have effects in hyperlipidemia and possibly nonalcoholic steatohepatitis, they also indicate that FGF-21, in physiological concentrations, may fail to reverse NAFLD and may not be able to control obesity and other diseases, indicating a state of FGF-21 resistance or insensitivity that could not respond to administration of FGF-21 in supraphysiological concentrations. Interventional studies with FGF-21 analogs (eg, pegbelfermin, efruxifermin, BOS-580) in humans have provided some favorable results in Phase 1 and Phase 2 studies. However, the definite effect of FGF-21 on NAFLD may be clarified after the completion of the ongoing clinical trials with paired liver biopsies and histological endpoints. The aim of this review is to critically summarize experimental and clinical data of FGF-21 in NAFLD, in an attempt to highlight existing knowledge and areas of uncertainty, and subsequently, to focus on the potential therapeutic effects of FGF-21 and its analogs in NAFLD.

项与 Efimosfermin alfa 相关的新闻（医药）

2025-05-15

·PMLiVE

GSK to acquire Boston’s liver disease candidate efimosfermin in deal worth up to $2bn

GSK has announced that it will be acquiring Boston Pharmaceuticals’ phase 3-ready liver disease candidate in a deal worth up to $2bn. Efimosfermin alfa is an investigational drug in clinical development to treat and prevent the progression of steatotic liver disease (SLD), a condition characterised by the buildup of fat in the liver and associated with inflammation and fibrosis. SLD, including metabolic dysfunction-associated steatohepatitis (MASH) and alcohol-related liver disease (ALD), affects approximately 5% of the global population and represents an area of significant unmet medical need, according to GSK. Given as a once-monthly subcutaneous injection, efimosfermin is fibroblast growth factor 21 (FGF21) analog therapeutic that has already been shown in a phase 2 trial to “rapidly and significantly” reverse liver fibrosis and stop its progression in patients with moderate-to-advanced MASH. The drug will also be evaluated in ALD and, “given its direct anti-fibrotic mechanism of action”, GSK said the asset could address more advanced stages of SLD and be used in combination with its siRNA therapeutic GSK’990, which is currently in development for other subsets of SLD patients. GSK’s chief scientific officer, Tony Wood, said efimosfermin “has the potential to define a new standard-of-care with its monthly dosing and tolerability profile”. He continued: “Efimosfermin will significantly expand our hepatology pipeline and provide us the opportunity to develop a new potential best-in-class medicine with first launch expected in 2029. It complements GSK‘990, also in development for ALD and MASH, offering GSK options to develop both monotherapy and potential combinations to improve patient outcomes.” GSK will gain access to efimosfermin by acquiring Boston’s subsidiary BP Asset IX for $1.2bn upfront and up to $800m in success-based milestone payments. The drugmaker will also be responsible for success-based milestone payments as well as tiered royalties for efimosfermin owed to Novartis Pharma. Elias Zerhouni, chair of the Boston’s board, said: “We are delighted that GSK… recognised efimosfermin’s potential to address a growing global public health concern and unmet medical need. Together, we look forward to efimosfermin’s ongoing journey to become a best-in-class treatment for patients with SLD.”

临床2期

2025-05-14

·药明康德

突破性小分子疗法3期结果积极！有望年底获批上市；GSK囊获潜在“best-in-class”肝病疗法……

GSK囊获潜在“best-in-class”肝病疗法今日，GSK与Boston Pharmaceuticals宣布达成协议，GSK将收购Boston Pharmaceuticals的主打疗法efimosfermin alfa。该疗法目前处于3期准备阶段，用于治疗和预防脂肪变性肝病（SLD）的进展。根据协议，GSK将支付Boston Pharmaceuticals共12亿美元的预付款，并另有潜在总计8亿美元的里程碑款项。Efimosfermin是一种在研、潜在“best-in-class”、每月一次注射的成纤维细胞生长因子21（FGF21）类似物，旨在调节关键代谢途径以减少肝脏脂肪、改善肝脏炎症并逆转代谢功能障碍相关脂肪性肝炎（MASH）患者的肝纤维化。该药物在未来可能开发用于治疗酒精性肝病（ALD），MASH与ALD均属于SLD。鉴于efimosfermin的直接抗纤维化作用机制以及GSK基于人类遗传学和疾病表型研究的数据洞察，该药物有潜力针对SLD的更晚期阶段，并可能与GSK正在开发、用于其他SLD患者亚群的siRNA疗法GSK'990联用。最近一项2期试验的数据显示，efimosfermin能快速显著逆转肝纤维化并阻止其进展，且耐受性良好。该试验旨在评估每月一次皮下注射efimosfermin对经活检证实的中度至重度（F2或F3）MASH患者的疗效和安全性。这些数据表明，与其他治疗方法相比，efimosfermin可能带来更大的纤维化改善，且预期其益处独立于胰高血糖素样肽-1（GLP-1）疗法。此外，efimosfermin还可能降低甘油三酯并改善血糖控制，这对常伴有心脏代谢共病的MASH患者尤为重要。Efimosfermin还具备低免疫原性和延长的半衰期，提供了每月给药方案和改善患者便利性的潜力。SLD是一个存在显著未满足医疗需求的领域，全球约5%的人口受其影响，而患者的治疗选择有限。SLD的特征是肝脏脂肪堆积（脂肪变性），伴随炎症和纤维化。其中ALD影响全球约2600万患者，与MASH一起是美国肝移植的主要原因，给医疗资源带来重大负担。诺和诺德达成22亿美元小分子疗法合作Septerna公司与诺和诺德（Novo Nordisk）今日宣布达成一项全球独家合作与许可协议，旨在共同发现、开发并商业化用于治疗肥胖、2型糖尿病及其他心脏代谢疾病的口服小分子药物。双方将率先启动四项开发项目，针对一种或多种特定的G蛋白偶联受体（GPCR）靶点开展潜在小分子疗法的研发，这些靶点包括GLP-1、GIP和胰高血糖素受体。GPCR是细胞膜受体中最大且最具多样性的家族之一，有数百种不同的GPCR在人体几乎所有器官系统中调控着生理过程。Septerna公司通过其专有的Native Complex Platform平台，致力于充分释放GPCR疗法的潜力。该公司专注于在多个治疗领域中开发口服小分子药物管线，初期聚焦于内分泌、免疫与炎症、以及代谢性疾病领域。根据协议条款，Septerna有资格从诺和诺德获得总计约22亿美元的付款，包括首付款及研发、开发和商业化里程碑付款。其中包含超过2亿美元的首付款和近期里程碑付款。合作开发项目中的所有研发费用将由诺和诺德承担。双方将联合开展从发现阶段到开发候选物选择阶段的研究活动。自IND支持性研究阶段起，诺和诺德将全权负责全球范围内的所有开发与商业化工作。艾伯维达数十亿美元siRNA疗法开发合作艾伯维（AbbVie）与ADARx Pharmaceuticals今日宣布达成一项合作与许可选择权协议，旨在联合开发适用于多个疾病领域的小干扰RNA（siRNA）疗法，这些领域包括神经科学、免疫学和肿瘤学。此次战略合作将充分发挥ADARx在RNA发现方面的专业能力及其专有的siRNA技术，该技术有望实现持久且精确的mRNA沉默。艾伯维则将在抗体工程、抗体偶联药物以及组织递送策略等方面提供专业支持，以助力ADARx的药物发现工作。根据协议条款，ADARx将获得3.35亿美元的预付款，并有资格获得数十亿美元包含里程碑付款的款项。突破性小分子疗法3期结果积极！有望年底获批上市日前，Cytokinetics公布了MAPLE-HCM临床3期试验的积极顶线结果。分析显示，其在研小分子抑制剂aficamten单药用于治疗有症状的梗阻性肥厚型心肌病（HCM）患者时，疗效优于现有标准疗法。该试验的完整结果预计在即将召开的医学会议上公布。Aficamten目前正在接受美国FDA的审查，PDUFA日期为2025年12月26日。MAPLE-HCM是一项多中心、随机、双盲、活性对照的临床3期试验，在175例有症状的梗阻性HCM患者中比较aficamten单药与现有标准治疗β受体阻滞剂美托洛尔相较的疗效与安全性。试验主要终点是通过心肺运动试验（CPET）测量的从基线至第24周的峰值摄氧量（pVO2）变化。次要终点包括堪萨斯城心肌病问卷（KCCQ）评分从基线至第24周的变化、纽约心脏协会（NYHA）心功能分级改善≥1级的患者比例，以及左心室质量指数（LVMI）、左心房容积指数（LAVI）、Valsalva动作后左心室流出道梯度（LVOT-G）和心衰生物标志物NT-proBNP的变化。分析显示，MAPLE-HCM达到了主要终点，与活性对照药物相比，aficamten在基线至第24周的峰值摄氧量改善方面显示出统计学显著性优势。在MAPLE-HCM试验中，aficamten的安全性和耐受性特征亦优于对照组。Aficamten是一种在研、潜在“best-in-class”的选择性小分子心肌肌球蛋白抑制剂。Aficamten旨在减少每个心动周期中活跃的肌动蛋白-肌球蛋白交联桥数量，从而抑制与HCM相关的心肌过度收缩。在临床前模型中，aficamten通过直接结合心肌肌球蛋白上一个独特的选择性变构结合位点来降低心肌收缩力，从而阻止肌球蛋白进入力产生状态。Aficamten曾获得美国FDA和中国国家药品监督管理局（NMPA）授予的突破性疗法认定，用于治疗有症状的梗阻性HCM。参考资料：[1] GSK to acquire efimosfermin, a phase III-ready potential best-in-class specialty medicine to treat and prevent progression of steatotic liver disease (SLD). Retrieved May 14, 2025 from https://www.gsk.com/en-gb/media/press-releases/gsk-to-acquire-efimosfermin-a-phase-iii-ready-potential-best-in-class-specialty-medicine-to-treat-and-prevent-progression-of-steatotic-liver-disease-sld/[2] Novo Nordisk A/S: Septerna and Novo Nordisk to collaborate on oral small molecule medicines for obesity and other cardiometabolic diseases. Retrieved May 14, 2025 from https://ir.septerna.com/news-releases/news-release-details/novo-nordisk-septerna-and-novo-nordisk-collaborate-oral-small[3] AbbVie and ADARx Pharmaceuticals Announce Collaboration and License Option Agreement to Develop Next-Generation siRNA Therapies Across Multiple Therapeutic Areas. Retrieved May 14, 2025 from https://www.adarx.com/abbvie-and-adarx-pharmaceuticals-announce-collaboration-and-license-option-agreement-to-develop-next-generation-sirna-therapies-across-multiple-therapeutic-areas/[4] Cytokinetics Announces Positive Topline Results From MAPLE-HCM. Retrieved May 14, 2015 from https://ir.cytokinetics.com/news-releases/news-release-details/cytokinetics-announces-positive-topline-results-maple-hcm免责声明：本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。版权说明：欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。分享，点赞，在看，聚焦全球生物医药健康创新

siRNA上市批准临床3期引进/卖出临床2期

2025-05-14

·GBIHealth

2025Q1中国医药外贸简报：出口额增长4.39%，进口延续收缩态势

企业动态No.1 / 2025Q1中国医药外贸简报：出口额增长4.39%，进口延续收缩态势2025年5月13日，中国医药保健品进出口商会发布2025年第一季度（2025Q1）医药外贸情况简报。2025Q1中国医药保健品进出口总额达到470.88亿美元，同比微增0.38%。其中，出口额为266.32亿美元，同比增长4.39%，主要依赖西药原料、医疗器械耗材等传统优势产品的持续增长；进口额则延续收缩态势，同比下降4.42%至204.56亿美元，反映国内产业升级带来的进口替代效应。出口市场呈现日趋多元化格局。Q1对美出口46.39亿美元，同比增长9.6%；西药原料（维生素、激素中间体）和一次性耗材（注射器、手套）贡献主要增量。对欧盟市场整体出口额56.3亿美元，同比增长4.43%。新兴市场中，对一带一路国家出口108.8亿美元，同比增长5.23%；对俄罗斯、沙特阿拉伯和非洲市场的出口额分别增长12.54%、9.54%和11.18%。对日韩、印度的出口额小幅增长，但相对疲软。进口收缩体现了国产药品和器械加速替代的双重作用。西药类进口额117.85亿美元，同比下降2.03%；原料进口逆势增长22.52%至27.32亿美元，激素中间体、抗感染类原料采购激增。医疗器械进口额80.04亿美元（-7.38%），其中医院诊断与治疗设备进口下降7.01%。高端药品进口依赖度依然较高，如抗癌药、罕见病药等仍需从欧盟、瑞士进口，但增速已较往年放缓。->点击文末阅读原文，解锁完整双语新闻No.2 / 拜耳2025Q1财报：收入137.38亿欧元，处方药业务增长4.1%2025年5月13日，拜耳集团发布2025年第一季度财报，集团收入137.38亿欧元，同比下降0.1%，汇率造成的负面影响为5500万欧元。盈利下滑主要受作物科学事业部表现、集团长期激励计划（LTI）费用增加以及主要因高通胀带来的1.65亿欧元（2024年第一季度：2.06亿欧元）的负面影响。处方药业务的（处方药事业部）销售额增长了4.1%（经汇率与资产组合调整，下同）达45.48亿欧元。该事业部新产品实现显著增长，抗癌药物诺倍戈的增长率为77.5%，用于治疗与2型糖尿病相关的慢性肾病的可申达的增长率为86.6%。眼科药物艾力雅销售额也持续增长，增长率为4.7%。影像诊断业务同样实现了增长，主要是因为CT高压注射系统产品线和优维显的销量上涨。避孕产品曼月乐和优思悦系列亦实现强劲增长，涨幅分别为18.4%和14.1%。口服抗凝药物拜瑞妥的销售额则由于仿制药竞争压力（尤其在欧洲和日本等地）下降了31.2%，这在一定程度上抵消了上述积极影响。自我保健产品（健康消费品业务）的销售额同比增长2.5%，达到14.99亿欧元。在全球四大业务地区中的三个中实现了销售增长。增长很大程度上得益于北美和亚太地区的销量增长。其它推动因素包括各地区消化道健康品类的销售额同比增长12.7%；同时，在经历上一季度开局疲软后，本季度美国市场的感冒咳嗽类产品销售额有所回升。相比之下，过敏品类和营养品类销售额有所下降，后者的销售额同比下降5.2%。->点击文末阅读原文，解锁完整双语新闻No.3 / 诺和诺德合作平安健康，打造肥胖症全周期智慧管理生态2025年5月13日，诺和诺德与平安健康医疗科技有限公司（简称“平安健康”）宣布达成战略合作。双方将整合在肥胖症管理及公众健康教育领域的各自优势，共同构建覆盖“认知提升-诊疗干预-长期管理”的全周期服务闭环，助力科学减重理念落地。此次合作中，双方将基于平安健康的数字化生态设立“肥胖症科普专区”，构建全链条体重管理路径。用户可通过该专区内“健康自测”工具计算自身BMI值，快速完成体重状况分级与潜在健康风险筛查。该专区还将整合肥胖危害及科学减重科普知识，同步链接减重管理服务网点，方便用户查询所在城市的合作机构与药店。未来，诺和诺德和平安健康还将发挥各自的优势，共同探索数智化体重管理，助力肥胖患者实现长期体重管理。->点击文末阅读原文，解锁完整双语新闻No.4 / 诺诚健华2025Q1：营收激增130%至3.81亿元，扭亏为盈2025年5月14日，诺诚健华医药有限公司（诺诚健华，688428.SH）发布2025年第一季度（2025Q1）财报。公司报告期内总营业收入3.81亿元，比上年同期增长129.92%；净利润为0.14亿元，实现扭亏为盈。截至报告期末，公司持有现金及相关账户结余约77.78亿元，现金流充足。营业收入高速增长主要得益于核心产品BTK抑制剂奥布替尼（商品名：宜诺凯）销售收入持续增长，以及公司与 Prolium Bioscience Inc.（以下简称“Prolium”）达成授权许可的首付款所致。奥布替尼2025Q1共实现销售收入3.11亿元，同比增长89.22%；4月获批新增适应证，用于一线治疗慢性淋巴细胞白血病（CLL）/小淋巴细胞淋巴瘤（SLL）成人患者，后续有望进一步放量。2025年1月，诺诚健华、康诺亚及双方的合资公司共同与Prolium达成许可合作，授权Prolium开发和商业化CD20×CD3双特异性抗体CM355（ICP-B02），交易对价最高5.2亿美元。->点击文末阅读原文，解锁完整双语新闻No.5 / 20亿美元！GSK收购波士顿制药同类最佳脂肪性肝病疗法Efimosfermin2025年5月14日，GSK plc（NYSE：GSK）与波士顿制药公司宣布，双方已达成协议，GSK将收购波士顿制药公司的子公司BP Asset IX，Inc.，以获取主要资产efimosfermin alfa。Efimosfermin是一种处于Ⅲ期临床前的潜在同类最佳的专科药物，用于治疗和预防脂肪性肝病（SLD）的进展。根据协议，GSK将支付12亿美元的预付款，并可能根据成功达成的里程碑额外支付总额为8亿美元的款项。此外，GSK还将负责支付efimosfermin应向诺华制药股份有限公司支付的成功里程碑款项以及分级特许权使用费。Efimosfermin是一种处于研究阶段的药物，是一种长效FGF21变体的每月一次皮下注射剂，旨在调节关键代谢途径，以减少肝脏脂肪堆积、减轻肝脏炎症并逆转MASH患者的肝脏纤维化。Efimosfermin目前正在针对中度至重度纤维化（包括肝硬化）进行试验，目前尚未在全球任何地方获得处方许可。鉴于efimosfermin的直接抗纤维化作用机制以及GSK在人类遗传学和疾病表型研究数据中获得的见解，efimosfermin有可能解决更晚期的SLD，并与GSK’990（一种正在开发的用于其他SLD患者亚群的siRNA治疗药物）联合使用。收购efimosfermin进一步加强了GSK的肝脏疾病专科药物研发管线，旨在解决纤维化性肝病的病毒性（慢性乙型肝炎）和脂肪性（SLD）病因。波士顿制药公司是B-Flexion的投资组合公司，B-Flexion是一家私人创业投资公司，管理与Bertarelli家族相关的联合基金和投资。->点击文末阅读原文，解锁完整双语新闻全球医疗情报领导者解锁隐藏在数据中的商业潜力关于 G B I”自从2002年成立以来，GBI始终以技术为驱动，为药企、器械及行业相关服务商提供贯穿生命周期的全球药品市场竞争数据、全球行业资讯、HCPs洞察、全国医疗器械数据等商业信息与洞察，助力企业在进行战略布局和决策时，脱颖而出。历经20余年的深耕细作GBI已成为95%以上跨国药企、国内头部药企、咨询与投资机构等医疗圈灯塔用户值得信赖的长期合作伙伴。联系我们投稿 | 发稿 | 媒体合作▶ olivia.xu@generalbiologic.com数据库 | 咨询服务 | 资讯追踪▶ 点击左下“阅读原文”完成表单填写点击阅读原文，解锁完整双语新闻

财报

100 项与 Efimosfermin alfa 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
代偿期肝硬化	临床2期	美国	Boston Pharmaceuticals, Inc.	2025-04-09
非酒精性脂肪性肝炎	临床2期	美国	Boston Pharmaceuticals, Inc.	2021-09-30
肥胖	临床1期	美国	Novartis Pharmaceuticals Corp.	2018-02-26

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04880031 (BOS-580-201, Biospace) 人工标引	临床2期	非酒精性脂肪性肝炎	84	Efimosfermin alfa 300 mg	鹽餘觸積獵襯憲壓鹹積(憲獵選築築鬱膚憲築壓) = 構壓夢築艱蓋願鏇淵廠憲衊蓋憲壓艱鏇簾窪積 (製簾簾鏇簾鑰顧衊壓膚 ) 更多	积极	2024-11-15
				Placebo	鹽餘觸積獵襯憲壓鹹積(憲獵選築築鬱膚憲築壓) = 遞積製顧選膚蓋築蓋齋憲衊蓋憲壓艱鏇簾窪積 (製簾簾鏇簾鑰顧衊壓膚 ) 更多
NASH_TAG2024	临床2期	-	102	BOS-580	觸淵蓋築鹹積鹽壓網遞(觸窪願獵夢繭積網觸範) = 構鹹簾鏇築鏇網鹽鹹餘網糧鹽鹽築鏇衊鬱鏇選 (壓製鑰製遞顧憲遞窪廠 )	积极	2024-01-04
				Placebo	觸淵蓋築鹹積鹽壓網遞(觸窪願獵夢繭積網觸範) = 蓋廠鏇選夢鬱襯選遞壓網糧鹽鹽築鏇衊鬱鏇選 (壓製鑰製遞顧憲遞窪廠 )
NCT04880031 (Biospace) 人工标引	临床2期	非酒精性脂肪性肝炎	102	overall	築壓積繭構夢膚顧窪壓(窪鏇鹹艱夢鏇鏇選積顧) = No treatment emergent adverse events of hypoglycemia were reported in any patient enrolled in the study. 膚鬱願製齋糧糧構醖壓 (壓顧衊構餘廠夢膚醖遞 ) 更多	积极	2023-11-10
				BOS-580 (HbA1c≥6.5%)
NCT03466203 (Pubmed \| J Clin Endocrinol Metab)	临床1期	高甘油三酯血症 \| 肥胖	64	LLF580 300 mg	鏇糧鑰獵醖繭顧選壓簾(願範構窪願糧壓鹽選糧) = higher incidence of generally mild to moderate gastrointestinal adverse effects 鏇繭蓋願糧鬱遞鏇餘餘 (築憲獵鑰顧衊襯鑰憲積 )	-	2021-08-25